12-Epi-Napelline Inhibits Leukemia Cell Proliferation via the PI3K/AKT Signaling Pathway In Vitro and In Vivo

Figure 6

12-Epi-napelline inhibited tumor growth in vivo. Mice were subcutaneously injected with tumor cells for tumor formation, and when the volume of tumor was measureable (approximately 100 mm³), mice were subjected to 12-epi-napelline (100 mg/kg·d) or DMSO. (a) The growth curve of tumor. (b) The typical photos of tumor. The results displayed that treatment with 12-epi-napelline inhibited tumor growth and decreased the tumor burden compared with the control (n = 6, ). Data were shown as mean ± standard deviation. (c) Typical photos of immunohistochemical staining of AKT and Bcl-2 in tumor tissues (magnification: ×200). (d) Average staining intensities of AKT and Bcl-2. Staining intensities were evaluated according to the number of positive cells in six random fields. The results revealed that 12-epi-napelline treatment reduced AKT and Bcl-2 expression (). (e) Typical photos of TUNEL staining in the tumor tissues (magnification: ×200). (f) Apoptotic index within tissues. The experimental group showed a significant increase in apoptotic cells in the tumor tissues.

(a)

(b)

(c)

(d)

(e)

(f)